Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 538-543

  Soumerai, Jacob D ^a,b   Hellmann, Matthew D ^a,b   Feng, Yang ^c   Sohani, Aliyah R ^b,d   Toomey, Christiana E ^a   Barnes, Jeffrey A ^a,b   Takvorian, Ronald W ^a,b   Neuberg, Donna ^c   Hochberg, Ephraim P ^a,b   Abramson, Jeremy S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diffuse large B cell lymphoma; DLBCL; Non Hodgkin lymphoma; PMBCL; Primary mediastinal B cell lymphoma; R CHOP

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84894480056     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.810738     Document Type: Article

References (23)

1. Armitage JO Weisenburger DD New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol 1998 16 2780-2795
2. Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: WHO; 2008. pp. 250-251
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242
4. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127
5. Pfreundschuh M, Schubert J, Ziepert M, et al. Sixversus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116
6. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 ; 7 : 379-391
7. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study . Ann Oncol 2011 ; 22 : 664-670
8. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006 ; 17 : 123-130
9. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239-249
10. Savage KJ, Yenson PR, Shenkier T, et al. The outcome ofprimary mediastinal Large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 2012;120(Suppl. 1): Abstract 303
11. [II] Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372-376
12. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002 ; 87 : 1258-1264
13. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691-699
14. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15:1646-1653
15. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437
16. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886
17. Straus DJ. Long-term survivorship at a price: late-term, therapy-Associated toxicities in the adult hodgkin lymphoma patient. Ther Adv Hematol 2011 ; 2 : 111-119
18. Witzens-Harig M, Ho AD, Kuhnt E, et al. Primary mediastinal B cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: 5-year results of the Mabthera International Trial Group (MInT) Study. Blood 2012;120(Suppl. 1): Abstract 1612
19. Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin AdvHematol Oncol 2009;7:125-133
20. Abou-Elella AA , Weisenburger DD, Vose JM , et al . Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999 ; 17 : 784-790
21. Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993 ; 11 : 1336-1343
22. Bishop PC , Wilson WH , Pearson D, et al . CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999;17:2479-2485
23. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-Adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013 ; 368 : 1408-1416 .